Patent SG-11201901712Y-A (SG)
Title: Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
Inventor: BERNETT MATTHEW
IPC: C07K16/46
Filed: 2017-08-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT omit °nolo olomum m11°111E11 oimIE (10) International Publication Number WO 2018/045110 Al \". 0.39 = 0.58 RI= 0.313 Ft 2 = 0.61 • Bladder • Breast • Cobn a Head & Neck • Kidney • Lung-Aden • Lung Squamout • Ovarian Pancreatic Prostate • Melanoma Log PD1 mRNA (51) International Patent Classification: C07K 16/46 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/049497 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/381,239 30 August 2016 (30.08.2016) US 62/456,033 07 February 2017 (07.02.2017) US 62/479,723 31 March 2017 (31.03.2017) US 15/623,314 14 June 2017 (14.06.2017) US (71) Applicant: XENCOR, INC. [US/US]; 111 West Lemon Avenue, Monrovia, CA 91016 (US). (72) Inventors: BERNETT, Matthew; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). MOORE, Gregory; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). DESJARLAIS, John; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). HEDVAT, Michael; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). BON- ZON, Christine; C/o Xencor, Inc., 111 West Lemon Av- enue, Monrovia, CA 91016 (KH). (74) Agent: NGUYEN, Louis, T. et al.; Morgan, Lewis & Bock- ius, Llp, One Market, Spear Street Tower, San Francisco, CA 94105 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RE- CEPTORS Figure 1 CRICIII I O ;2 (57) : The present invention is directed to bispedfic, heterodimeric immunomodulatory antibodies.